NewsAI-assisted

Charles River Unveils Apollo™ for CRADL®: Accelerating Drug Discovery

Apollo™ simplifies research with seamless tools, boosting efficiency in drug discovery programs.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Jan 22, 2025Updated Jun 26, 2025 · 2 min read
Charles River Unveils Apollo™ for CRADL®: Accelerating Drug Discovery
https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.criver.com%2Fproducts-services%2Fdiscovery-services%2Fdiscovery-facilities&psig=AOvVaw0D41pz9401L-2grCqRcDHC&ust=1737622618540000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCID_oez6iIsDFQAAAAAdAAAAABAE
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

Charles River Laboratories International, Inc. has introduced Apollo™ for CRADL®, a secure, cloud-based platform that revolutionizes vivarium rental services by streamlining research processes. Designed to support clients launching or expanding drug discovery programs, Apollo simplifies onboarding and integrates seamlessly with Charles River’s Research Models Online Ordering System, training tools, and other services. This centralized platform provides direct control over reservations, protocol management, and research execution, enabling faster and more efficient project initiation.

Mark Mintz, Corporate Senior Vice President and CIO of Charles River, emphasized Apollo's role in driving the company's digital transformation, offering clients access to real-time data and tools that optimize research processes. With applications extending across safety assessment, biologics, oncology studies, and more, Apollo represents a comprehensive innovation aimed at accelerating drug discovery and development. By reducing administrative hurdles and enhancing operational efficiency, Charles River continues to lead in delivering cutting-edge solutions for the scientific community.

TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →